⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
RAINBOW - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.3
| Stock Code | RAINBOW | Market Cap | 11,357 Cr. | Current Price | 1,119 ₹ | High / Low | 1,646 ₹ |
| Stock P/E | 46.3 | Book Value | 156 ₹ | Dividend Yield | 0.27 % | ROCE | 18.3 % |
| ROE | 16.7 % | Face Value | 10.0 ₹ | DMA 50 | 1,207 ₹ | DMA 200 | 1,315 ₹ |
| Chg in FII Hold | -2.61 % | Chg in DII Hold | 2.03 % | PAT Qtr | 65.8 Cr. | PAT Prev Qtr | 73.2 Cr. |
| RSI | 35.5 | MACD | -18.8 | Volume | 3,33,693 | Avg Vol 1Wk | 1,58,974 |
| Low price | 1,009 ₹ | High price | 1,646 ₹ | PEG Ratio | 2.60 | Debt to equity | 0.46 |
| 52w Index | 17.3 % | Qtr Profit Var | -1.73 % | EPS | 24.2 ₹ | Industry PE | 43.5 |
📊 Core Financials
- Revenue Growth: Quarterly PAT declined from ₹73.2 Cr to ₹65.8 Cr (-1.73%), showing short-term weakness.
- Profit Margins: Margins remain healthy, supported by hospital operations and healthcare services.
- Debt Ratios: Moderate debt-to-equity (0.46), manageable for expansion-driven healthcare business.
- Cash Flows: Stable due to recurring healthcare demand, though expansion costs may pressure cash flows.
- Return Metrics: ROCE at 18.3% and ROE at 16.7% → strong efficiency for the sector.
💹 Valuation Indicators
- P/E Ratio: 46.3 vs Industry PE of 43.5 → slightly overvalued.
- P/B Ratio: ~7.17 (Price ₹1,119 / Book Value ₹156) → premium valuation.
- PEG Ratio: 2.60 → suggests growth is priced expensively.
- Intrinsic Value: Current price moderately above fair value, limiting upside potential.
🏢 Business Model & Competitive Advantage
- Rainbow Children’s Medicare operates in pediatric and maternity healthcare services.
- Competitive advantage lies in specialization, brand reputation, and growing demand for quality healthcare.
- Strong return ratios and moderate leverage support overall health, though valuations are stretched.
📈 Entry Zone & Long-Term Guidance
- Entry Zone: Attractive accumulation range between ₹1,050 – ₹1,100 (near support levels).
- Long-Term Holding: Suitable for investors seeking exposure to healthcare growth, but caution advised due to premium valuations.
✅ Positive
- Strong ROCE (18.3%) and ROE (16.7%).
- Specialized healthcare services with strong brand presence.
- DII holdings increased (+2.03%).
- Moderate debt-to-equity (0.46).
⚠️ Limitation
- High P/E ratio (46.3) compared to industry average.
- Premium P/B ratio (~7.17).
- PEG ratio (2.60) suggests growth is expensive.
- Dividend yield negligible (0.27%).
📉 Company Negative News
- Quarterly PAT declined (-1.73%).
- FII holdings reduced (-2.61%).
- Weak technical indicators (RSI 35.5, MACD -18.8).
📈 Company Positive News
- DII holdings increased (+2.03%).
- Strong brand positioning in pediatric and maternity healthcare.
- Consistent demand for specialized healthcare services.
🏭 Industry
- Healthcare industry growing with rising demand for specialized services.
- Industry PE at 43.5, showing Rainbow trades at a slight premium.
🔎 Conclusion
Rainbow Children’s Medicare offers strong fundamentals with healthy return ratios and brand strength in specialized healthcare. However, valuations are stretched with high P/E and P/B ratios, and short-term profit growth is weak. Investors may accumulate near support levels for long-term exposure to healthcare growth, but should remain cautious of overvaluation risks.